Yongling Wan

This inventor holds 4 USPTO granted patents, plus 1 CIPO patent and 4 EPO patents. Top assignee: Tobishi Pharmaceutical Co., Ltd.. Active years: 2010-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yongling Wan. Retrieved from https://idiyas.com/inventor/yongling-wan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4

% Patents Active = 75.0

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 2)

Average Co-Inventor Count = 2.8

ph-index = 1

Location History:

Beijing, CN (2010 - 2014)
Haidian District, CN (2020)

Company Filing History:

4 out of 13

Tobishi Pharmaceutical Co., Ltd.

patents

Years Active: 2010-2020

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10624910 - Thrombin-like enzyme for reducing a side effect of an anticancer drug (2020-04-21),

2. 8795655 - Therapeutic agent for a lower urinary tract disease and an agent for improving a lower urinary tract symptom (2014-08-05),

3. 8481047 - Malignant tumor-inhibiting preparation comprising Des A fibrin (2013-07-09),

4. 7691371 - Preparation comprising batroxobin for inhibiting local invasion of malignant tumors (2010-04-06),

Title: Yongling Wan: Innovator in Pharmaceutical Advancements

Introduction

Yongling Wan is a prominent inventor based in Beijing, China. He has made significant contributions to the field of pharmaceuticals, particularly in developing therapeutic agents for various medical conditions. With a total of 4 patents to his name, his work is recognized for its potential impact on healthcare.

Latest Patents

Among his latest patents, Yongling Wan has developed a thrombin-like enzyme aimed at reducing the side effects of anticancer drugs. This invention provides a novel agent that can mitigate adverse reactions associated with cancer treatments. Additionally, he has created a therapeutic agent for lower urinary tract diseases, including conditions such as cystitis and benign prostatic hyperplasia. This agent is designed to improve symptoms related to these often-refractory diseases.

Career Highlights

Yongling Wan is currently associated with Tobishi Pharmaceutical Co., Ltd., where he continues to innovate and contribute to the pharmaceutical industry. His work is characterized by a commitment to addressing complex medical challenges through scientific research and development.

Collaborations

Yongling has collaborated with notable colleagues, including Hirobumi Senga and Lishui Chang. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in their field.

Conclusion

Yongling Wan's contributions to pharmaceutical innovations highlight his dedication to improving patient outcomes through scientific advancements. His patents reflect a commitment to addressing significant health issues, making him a valuable figure in the realm of medical research.

Profile summary based on public USPTO records.